I’m proud to share a significant step forward for Candel Therapeutics: Positive Interim Data for CAN-3110 in Recurrent Glioblastoma & New Publication in Science Translational Medicine. Today, we announced positive interim survival results from our phase 1b study of CAN-3110

Impressive to get so many things wrong in one report by Jacob Plieth from @ApexOnco . 1. The name of CAN-2409 is aglatimagene besadenovec, not agla-vec. 2. The data of the phase 2a clinical trial of CAN-240 in NSCLC has never disappointed. They are in fact very encouraging,

Dr. Charu Aggarwal from @PennMedicine is presenting CAN-2409 NSCLC data at @IASLC 2025. Candel’s phase 2a trial in ICI-resistant patients showed 21.5 months median OS vs 9.8-11.8 months with standard chemotherapy. https://t.co/JmzEs6R8va #WCLC25 #LungCancer #ClinicalData

Our CEO @paulpetertak will present at the 44th Annual Canaccord Genuity Growth Conference. Be sure to connect with us if you're attending the conference. https://t.co/eZkgnLI0jl $CADL

I'm delighted to join MIB’s newly formed Scientific Advisory Board alongside a group of outstanding experts!

Great day for ⁦@CandelTx⁩ !!!!

Join our investor conference call on Tuesday, June 3 at 1:00 PM ET following our #ASCO25 presentation. Our management team & leading prostate cancer specialists will discuss our phase 3 CAN-2409 results. Find more details here: https://t.co/5W33SRMebV $CADL #ProstateCancer

Candel Therapeutics is set to host a webcast and conference call on Tuesday, June 3, 2025, at 1:00 PM ET. The event will delve into the promising phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer. These results showcased a notable 30%

New in @NeuroOnc! Our phase 1b trial of CAN-2409 + nivolumab in newly diagnosed high-grade glioma shows promising safety & survival data with immune activation supporting CAN-2409's pan-tumor potential. Read more: https://t.co/h12KNkyhD0 $CADL

Combination of surgical upfront immunotherapy with aglatimagene besadenovec (CAN-2409), followed by chemoradiation and then adjuvant nivolumab for newly diagnosed glioblastoma (Wen et al. March 2025, @NeuroOnc). @EAChiocca & @paulpetertak

The collaboration between Candel Therapeutics and IDEA Pharma comes at a critical time as we prepare for our BLA submission for CAN-2409 in prostate cancer. Candel will gain access to a dedicated team of experts with extensive experience in oncology commercialization and

Molecular and spatial analysis of tertiary lymphoid structures in Sjogren’s syndrome https://t.co/6cYhlyCAeT @NatureComms @baroneExpMed

https://t.co/1NF56Lt1Pa

@adamfeuerstein @CandelTx Manufacturing. While we continued to advance analytical development and comparability studies successfully, and locked the process, we did not want to spend tens of millions of $$ on large scale manufacturing before data read out - a concept that we call dynamic portfolio

https://t.co/5Ivy3CciCw

We hope we will deliver the data and regulatory approvals in prostate cancer to enable a paradigm shift in how these patients will be treated in the future. #CandelTherapeutics #viral #immunotherapy #CAN-2409 $CADL

https://t.co/yZY07e3sIP

Late stage melanoma represents a life threatening unmet clinical need. Come and visit our poster during SITC to discuss our plans to leverage our first in class viral immunotherapy CAN-3110 to fight this terrible disease.

Safe and feasible intratumoral CAN-2409 delivery on outpatient basis can reinvigorate immune response in ICI refractory #NSCLC and extend survival. @CharuAggarwalMD @Perlmutter_CC @nyulangone #ASCO24

@CharuAggarwalMD